Sarepta Therapeutics (SRPT) Tops Q3 EPS by 57c
Tweet
Share
E-mail
Get Alerts SRPT Hot Sheet
Join SI Premium – FREE
Sarepta Therapeutics (NASDAQ: SRPT) reported Q3 EPS of ($0.13), $0.57 better than the analyst estimate of ($0.70). Revenue for the quarter came in at $399.4 million versus the consensus estimate of $337.91 million.
For earnings history and earnings-related data on Sarepta Therapeutics (SRPT) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Ennis (EBF) Reports In-Line Q1 EPS
- DraftKings (DKNG) Reiterated at Buy by Benchmark as Environment Stays Bettor-Friendly
- Rayonier Advanced Materials names Daniel Krawczyk as CEO
Create E-mail Alert Related Categories
EarningsRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
